文献速递慢病防控与筛查免疫规划

流感疫苗在减少心力衰竭患者不良事件方面的效果:系统综述与荟萃分析

Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis.
PubMed 文献 · Vaccine · 2022-05-11

该系统综述与荟萃分析综合7项非随机研究、共247,842例心力衰竭患者的数据,评估接种流感疫苗后12个月内不良血管事件与死亡风险。结果显示,接种者全因死亡风险(RR=0.75,95%CI 0.71-0.79)和心血管相关死亡风险(RR=0.77,95%CI 0.73-0.81)均显著降低,但全因住院风险反而升高(RR=1.24,95%CI 1.13-1.35);证据确定性为低至极低。

要点

  • 接种流感疫苗与心力衰竭患者12个月内全因死亡风险降低相关(RR=0.75,95%CI 0.71-0.79)。
  • 心血管相关死亡风险亦降低(RR=0.77,95%CI 0.73-0.81),但证据确定性低。
  • 全因住院风险在接种者中更高(RR=1.24,95%CI 1.13-1.35),证据确定性极低且异质性明显。

核心结论

  • 流感疫苗接种似乎可减少心力衰竭患者的不良心血管事件,但证据确定性为低或极低。
  • 需要严格的随机对照试验证据进一步检验流感疫苗对心力衰竭患者的保护作用。

研究设计与样本

  • 系统综述与荟萃分析,全面检索MEDLINE与EMBASE数据库,完成研究筛选与质量评价并合成数据。
  • 纳入标准为研究对象是心力衰竭患者、接种流感疫苗并报告12个月内结局,且与未接种流感疫苗的心力衰竭患者比较。
  • 最终合成7项非随机研究,共247,842例患者。
  • 采用纽卡斯尔-渥太华量表评估偏倚风险,并完成GRADE评级。
  • 采用随机效应荟萃分析估计合并风险比(RR)、95%置信区间(CI),并用I2统计量评估异质性。

主要发现

  • 全因死亡风险在心力衰竭患者接种流感疫苗后12个月内显著降低(RR=0.75,95%CI 0.71-0.79;P<0.0001),证据确定性极低。
  • 心血管相关死亡风险显著降低(RR=0.77,95%CI 0.73-0.81;P<0.0001),证据确定性低。
  • 基于两项研究,接种疫苗的心力衰竭患者全因住院的合并风险更高(RR=1.24,95%CI 1.13-1.35;P<0.0001),证据确定性极低且异质性明显(I2=90%)。

关键数值与推荐

  • 评估的6项结局为:全因死亡、心血管相关死亡、全因住院、心血管相关住院、非致死性心肌梗死、非致死性卒中。
  • 心血管相关住院、非致死性心肌梗死与非致死性卒中均无符合条件的研究进行评估。
  • 全因死亡:RR=0.75,95%CI 0.71-0.79;P<0.0001;证据确定性极低。
  • 心血管相关死亡:RR=0.77,95%CI 0.73-0.81;P<0.0001;证据确定性低。
  • 全因住院:RR=1.24,95%CI 1.13-1.35;P<0.0001;基于两项研究;证据确定性极低;异质性I2=90%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据确定性为低或极低。
  • 全因住院分析仅基于两项研究,异质性明显(I2=90%)。
  • 纳入研究均为非随机研究。
  • 需要严格的随机对照试验证据进一步检验流感疫苗对心力衰竭患者的保护作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The association between influenza and adverse vascular events in patients with heart failure is well documented. The effect of the influenza vaccine on preventing such adverse events is uncertain. This systematic review and meta-analysis addressed whether vaccination against influenza reduces adverse vascular events and mortality in heart failure patients. METHODS: MEDLINE and EMBASE databases were comprehensively searched, study screening and quality assessment were completed, and data was synthesized. Eligible studies investigated heart failure patients who received the influenza vaccine, and reported outcomes within 12 months, compared to heart failure patients who did not receive the influenza vaccine. The following 6 outcomes were assessed: all-cause mortality, cardiovascular-related mortality, all-cause hospitalization, cardiovascular-related hospitalization, non-fatal myocardial infarction, and non-fatal stroke. Risk of bias was assessed using the Newcastle-Ottawa Scale and a GRADE assessment was completed. A random-effects meta-analysis was performed to estimate the pooled risk ratio (RR), 95% confidence intervals (CIs), and heterogeneity using I2 statistics. RESULTS: After synthesizing data from 7 non-randomized studies (247,842 patients), the results demonstrate the risk of all-cause mortality is significantly reduced within 12 months of a heart failure patient receiving the influenza vaccine (RR = 0.75, 95% CI 0.71-0.79; P<0.0001); very low certainty of evidence. The risk of cardiovascular-related mortality was significantly reduced (RR = 0.77, 95% CI 0.73-0.81; P<0.0001); low certainty of evidence. The pooled risk of all-cause hospitalization was higher among vaccinated heart failure patients (RR = 1.24, 95% CI 1.13-1.35; P<0.0001), based on two studies; very low certainty of evidence and considerable heterogeneity (I2 = 90%). No eligible studies assessed cardiovascular-related hospitalization, non-fatal myocardial infarction, or non-fatal stroke. CONCLUSIONS: Influenza vaccination appears to reduce adverse cardiovascular events, although the certainty of the evidence is low or very low. Rigorous randomized controlled trial evidence is needed to further examine the protective effect of the influenza vaccine in heart failure patients.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Gupta C, Sachdeva A, Khamar J, et al. Effectiveness of the influenza vaccine at reducing adverse events in patients with heart failure: A systematic review and meta-analysis. Vaccine. 2022. PMID: 35562195. doi:10.1016/j.vaccine.2022.04.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。